PL369527A1 - Podstawione związki benzimidazolowe i ich zastosowanie do leczenia raka - Google Patents

Podstawione związki benzimidazolowe i ich zastosowanie do leczenia raka

Info

Publication number
PL369527A1
PL369527A1 PL02369527A PL36952702A PL369527A1 PL 369527 A1 PL369527 A1 PL 369527A1 PL 02369527 A PL02369527 A PL 02369527A PL 36952702 A PL36952702 A PL 36952702A PL 369527 A1 PL369527 A1 PL 369527A1
Authority
PL
Poland
Prior art keywords
cancer
treatment
benzimidazole compounds
substituted benzimidazole
substituted
Prior art date
Application number
PL02369527A
Other languages
English (en)
Inventor
François Clerc
François Hamy
Isabelle Depaty
Odile Angouillant-Boniface
Stephanie Deprets
Chantal Carrez
Manfred Roesner
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of PL369527A1 publication Critical patent/PL369527A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL02369527A 2001-09-26 2002-09-26 Podstawione związki benzimidazolowe i ich zastosowanie do leczenia raka PL369527A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01402460A EP1298125A1 (en) 2001-09-26 2001-09-26 Substituted benzimidazole compounds and their use for the treatment of cancer

Publications (1)

Publication Number Publication Date
PL369527A1 true PL369527A1 (pl) 2005-05-02

Family

ID=8182891

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02369527A PL369527A1 (pl) 2001-09-26 2002-09-26 Podstawione związki benzimidazolowe i ich zastosowanie do leczenia raka

Country Status (35)

Country Link
US (1) US7041668B2 (pl)
EP (2) EP1298125A1 (pl)
JP (1) JP4510450B2 (pl)
KR (1) KR100891439B1 (pl)
CN (1) CN100346786C (pl)
AR (1) AR037096A1 (pl)
AT (1) ATE386517T1 (pl)
AU (1) AU2002337151B2 (pl)
BR (1) BR0212856A (pl)
CA (1) CA2461622C (pl)
CO (1) CO5570675A2 (pl)
CY (1) CY1107953T1 (pl)
DE (1) DE60225159T2 (pl)
DK (1) DK1432417T3 (pl)
EA (1) EA006802B1 (pl)
ES (1) ES2301682T3 (pl)
GT (1) GT200200190A (pl)
HR (1) HRPK20040293B3 (pl)
HU (1) HUP0401756A3 (pl)
IL (1) IL161059A0 (pl)
ME (1) MEP16808A (pl)
MX (1) MXPA04002042A (pl)
MY (1) MY135339A (pl)
NO (1) NO327008B1 (pl)
NZ (1) NZ531246A (pl)
PA (1) PA8555501A1 (pl)
PE (1) PE20030427A1 (pl)
PL (1) PL369527A1 (pl)
PT (1) PT1432417E (pl)
PY (1) PY0223362A (pl)
RS (1) RS50896B (pl)
SI (1) SI1432417T1 (pl)
UY (1) UY27452A1 (pl)
WO (1) WO2003028721A2 (pl)
ZA (1) ZA200401887B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20070208166A1 (en) * 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
FR2868421B1 (fr) * 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
EP1598348A1 (en) 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Novel pyridazinone derivatives as inhibitors of CDK2
EP1836161B1 (en) 2004-12-22 2016-07-20 BHI Limited Partnership Methods and compositions for treating amyloid-related diseases
CN101300251B (zh) * 2005-09-06 2011-08-03 史密丝克莱恩比彻姆公司 作为plk抑制剂的苯并咪唑噻吩化合物
FR2891273B1 (fr) * 2005-09-27 2007-11-23 Aventis Pharma Sa NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
SI2089417T1 (sl) 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
EP2212327A1 (en) * 2007-10-12 2010-08-04 Abbott Laboratories 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
FR2941950B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
WO2011091152A1 (en) * 2010-01-22 2011-07-28 Pablo Gastaminza Inhibitors of hepatitis c virus infection
BR112015013105B1 (pt) 2012-12-05 2022-02-08 Alnylam Pharmaceuticals, Inc Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
EP3340994A1 (en) 2015-08-25 2018-07-04 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2441201C2 (de) * 1974-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Anthelminthisch wirksame 2-Carbalkoxyamino-5(6)-phenyl-sulfonyloxy-benzimidazole und Verfahren zu ihrer Herstellung
DE2541752A1 (de) * 1975-09-19 1977-03-24 Hoechst Ag Anthelminthisch wirksame 2-carbalkoxyamino-5(6)-phenyl-sulfonyloxy- benzimidazole und verfahren zu ihrer herstellung
DE3247615A1 (de) * 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9900752D0 (en) * 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
YU21404A (sh) 2006-08-17
RS50896B (sr) 2010-08-31
HK1068551A1 (en) 2005-04-29
UY27452A1 (es) 2003-02-28
NZ531246A (en) 2006-06-30
AU2002337151B2 (en) 2007-04-26
JP4510450B2 (ja) 2010-07-21
EA006802B1 (ru) 2006-04-28
EP1432417A2 (en) 2004-06-30
HRP20040293A2 (en) 2005-06-30
HRPK20040293B3 (hr) 2007-06-30
NO327008B1 (no) 2009-04-06
CA2461622C (en) 2008-12-02
GT200200190A (es) 2003-11-11
MY135339A (en) 2008-03-31
ATE386517T1 (de) 2008-03-15
HUP0401756A3 (en) 2005-06-28
CA2461622A1 (en) 2003-04-10
CO5570675A2 (es) 2005-10-31
EP1298125A1 (en) 2003-04-02
CY1107953T1 (el) 2013-09-04
EA200400475A1 (ru) 2004-08-26
KR100891439B1 (ko) 2009-04-03
PY0223362A (es) 2004-04-01
PT1432417E (pt) 2008-05-23
US7041668B2 (en) 2006-05-09
NO20041214L (no) 2004-06-24
DE60225159T2 (de) 2009-02-19
US20050014811A1 (en) 2005-01-20
HUP0401756A2 (hu) 2005-01-28
WO2003028721A3 (en) 2003-12-11
IL161059A0 (en) 2004-08-31
BR0212856A (pt) 2004-09-14
ZA200401887B (en) 2005-05-31
DK1432417T3 (da) 2008-06-16
WO2003028721A2 (en) 2003-04-10
PE20030427A1 (es) 2003-06-20
SI1432417T1 (sl) 2008-08-31
JP2005504112A (ja) 2005-02-10
ES2301682T3 (es) 2008-07-01
DE60225159D1 (de) 2008-04-03
CN1558761A (zh) 2004-12-29
CN100346786C (zh) 2007-11-07
EP1432417B1 (en) 2008-02-20
KR20040048904A (ko) 2004-06-10
MEP16808A (bs) 2010-06-10
PA8555501A1 (es) 2003-06-30
AR037096A1 (es) 2004-10-20
MXPA04002042A (es) 2004-06-07

Similar Documents

Publication Publication Date Title
PL370029A1 (pl) Pochodne 2-amino-4-heteroaryloaminopirymidyny do stosowania w leczeniu raka
AU6048201A (en) Quinazoline derivatives for the treatment of tumours
PL375532A1 (pl) Związki benzimidazol-1-ilotiofenowe do leczenia nowotworów
IL164599A0 (en) Combination therapy for the treatment of cancer
IL161059A0 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
IL157425A0 (en) Treatment of solid tumours with paramycin derivatives
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
AU6147401A (en) Compositions and methods for the treatment of cancer
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
HUS2200036I1 (hu) Dihidroimidazolonok alkalmazása kutyák kezelésére
ZA200408767B (en) Immunoconjugates for the treatment of tumours
HUP0500424A2 (en) Combination therapy for the treatment of cancer
AU2003212634A8 (en) Compounds useful in the treatment of cancer
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith
PL368035A1 (pl) Kompozycje i sposoby leczenia raka
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
PL375564A1 (pl) Podstawione 5-chroman-5-ylo-etyloaminy i ich zastosowanie do leczenia jaskry
LT1496918T (lt) Natrio meta-arsenito naudojimas navikams gydyti
GB0119025D0 (en) Compounds and their therapeutic use
AU2002304883A1 (en) Device for the treatment of tumours
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
SI1680405T1 (sl) Bengamidni derivati in njihova uporaba za zdravljenje rakavih bolezni
AU2002350513A1 (en) Use of solasonine for the treatment of skin tumors

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)